Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 3/20 | 0.50 |
| ▸ | HTR2C | P28335 | 2/20 | 0.50 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.47 |
| ▸ | BAD | Q92934 | 1/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 7/20 | 0.44 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | DHFR | P00374 | 2/20 | 0.40 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19775787 | 0.98 | HTR2A (0.49) | HTR2AHTR2CBCL2L1BADTAAR1 | |
| SCHEMBL9720039 | 0.88 | BCL2L1 (0.54) | HTR2AHTR2CBCL2L1BADTBXA2R | |
| SCHEMBL172968 | 0.84 | PNMT (0.52) | HTR2AHTR2CBCL2L1BADTBXA2R | |
| SCHEMBL10602990 | 0.82 | PNMT (0.50) | HTR2AHTR2CBCL2L1BADTBXA2R | |
| Hydrochloric Acid SCHEMBL10647798 | 0.81 | PNMT (0.49) | HTR2AHTR2CBCL2L1BADTBXA2R | |
| SCHEMBL3886272 | 0.81 | BCL2L1 (0.52) | BCL2L1BADTBXA2RALDH1A1DHFR | |
| SCHEMBL10535124 | 0.80 | PNMT (0.52) | HTR2AHTR2CBCL2L1BADTBXA2R | |
| SCHEMBL7818234 | 0.79 | BCL2L1 (0.50) | BCL2L1BADTBXA2RALDH1A1DHFR | |
| SCHEMBL6368014 | 0.78 | BCL2L1 (0.44) | BCL2L1BADTBXA2RALDH1A1DHFR | |
| SCHEMBL6256898 | 0.78 | ALDH1A1 (0.44) | BCL2L1BADTBXA2RALDH1A1DHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111848494-B | Guanidine compounds and uses thereof | 伊谬诺米特医疗有限公司 | 2023-08-01 | — | — | CN | disclosed |
| EP-3131877-B1 | BIGUANIDE COMPOUNDS | IMMUNOMET THERAPEUTICS INC (US) | 2023-07-19 | — | — | EP | disclosed |
| US-11465989-B2 | Guanidine compounds and use thereof | ImmunoMet Therapeutics, Inc. (US) | 2022-10-11 | — | — | US | disclosed |
| CN-111848494-A | Guanidine compounds and uses thereof | 伊谬诺米特医疗有限公司 | 2020-10-30 | — | — | CN | disclosed |
| US-20170073331-A1 | GUANIDINE COMPOUNDS AND USE THEREOF | IMMUNOMET THERAPEUTICS INC. (US) | 2017-03-16 | — | — | US | disclosed |
| EP-3131877-A1 | GUANIDINE COMPOUNDS AND USE THEREOF | Immunomet Therapeutics Inc. (US) | 2017-02-22 | — | — | EP | disclosed |
| WO-2015160220-A1 | GUANIDINE COMPOUNDS AND USE THEREOF | HANALL BIOPHARMA CO., LTD. (KR) | 2015-10-22 | — | — | WO | disclosed |
| EP-0563132-B1 | TETRAPEPTIDE DERIVATIVES AND ANALOGUES | BLACK JAMES FOUNDATION (GB) | 1996-02-07 | — | — | EP | disclosed |
| US-5486597-A | GASTRIN ANTAGONIST AS ANTISECRETORY AGENTS OF GASTRIC JUICE FOR STOMACH CANCER | JAMES BLACK FOUNDATION LIMITED (GB) | 1996-01-23 | — | — | US | disclosed |
| WO-1992011284-A1 | TETRAPEPTIDE DERIVATIVES AND ANALOGUES | THE JAMES BLACK FOUNDATION LIMITED (GB) | 1992-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11465989-B2 | Guanidine compounds and use thereof | PC, TFAM, PCK2 | HTR2A 3793/4885HTR2C 4266/4885BCL2L1 2830/4885 |
| US-20170073331-A1 | GUANIDINE COMPOUNDS AND USE THEREOF | PC, TFAM, PCK2 | HTR2A 3793/4885HTR2C 4266/4885BCL2L1 2830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.